Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Diagnostic marker for diabetic vascular complications

A technology for complications and diabetes, which is applied in the field of diagnostic markers for diabetic vascular complications, and can solve problems such as accelerated vascular damage

Inactive Publication Date: 2008-07-02
FIBROGEN INC
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The mechanism by which diabetes and hypertension coexist and accelerate vascular damage has not yet been clarified

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic marker for diabetic vascular complications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1: Research Methods

[0036] This study used the following methods:

[0037] research group

[0038] The study population was the North American DCCT / EDIC study group, consisting of 1325 patients with type 1 diabetes among the original 1441 DCCT subjects. The original DCCT (Diabetes Control and Complications Trial, Diabetes Control and Complications Trial) study group consisted of men and women aged 13-40, who joined the study between 1983-1989 and had a history of diabetes for 1-15 years when they joined the study (The Diabetes Control and Complications Trial Research Group (1993) N Engl J Med 329:977-986). Half the patient population was randomly assigned to receive usual diabetes care and the other half to receive intensive diabetes care. In 1993, after an average follow-up period of 6.5 years, the DCCT study was stopped after intensive treatment clearly showed that the risk of retinopathy, nephropathy and neuropathy could be reduced (The Diabetes Control ...

Embodiment 2

[0048] Example 2: CTGF N Fragment Levels in the DCCT / EDIC Study Group of Type 1 Diabetes Patients

[0049] The clinical characteristics of the study population for which CTGF measurements were performed are listed in Table 1 (Clinical Characteristics of the DCCT / EDIC Study Group by Sex * ). The plasma levels of CTGF N fragments and the urinary excretion rate of CTGF N fragments were measured in 1052 patients with type 1 diabetes mellitus. The relationship between the logarithm of CTGF N-fragment and biochemical parameters in the study group of patients is listed in Table 2 (univariate regression analysis was performed to predict the logarithm of CTGF N-fragment level). The univariate regression coefficients in Table 2 can be interpreted as the log mean change in CTGF N fragment per unit change for a given covariate. Another explanation is that exp(β) is approximately equal to the relative increase in CTGF N fragment per unit change in covariate.

[0050] Table 1

[0051] ...

Embodiment 3

[0057] Example 3: Correlation between plasma CTGF N fragments and blood pressure

[0058] The results in Figure 1 show non-hypertensive (n = 668) and hypertensive (n = 382) patients (all patients were diagnosed with hypertension, systolic blood pressure > 140, diastolic blood pressure > 90; and treated with antihypertensive drugs) Estimated cumulative distribution of the logarithm of plasma CTGF N fragments. These results demonstrate that hypertensive subjects tend to have higher plasma CTGF N fragment log values ​​than normotensive subjects.

[0059] The mean logarithm of plasma CTGF N-fragment in patients with proven hypertension was significantly higher than that in patients without hypertension (3.36±0.04 ng / ml in the former versus 3.21±0.03 ng / ml in the latter, P=0.0005). The actual mean plasma CTGF level measured in hypertensive patients was 41.57±3.47 ng / ml, while the actual mean plasma CTGF level measured in normotensive patients was 32.28±1.81 ng / ml, P=0.0109. There...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention has discovered that connective tissue growth factor (CTGF) can be used as a diagnostic marker for the development and increased risk of progression of vascular disease.

Description

[0001] This application claims priority to US Provisional Application Serial No. 60 / 678,251, filed May 5, 2005, which is incorporated herein by reference in its entirety. technical field [0002] The present invention has discovered that connective tissue growth factor (CTGF) is a diagnostic marker indicative of an increased risk of development and progression of vascular disease. Background technique [0003] Diabetes is associated with increased morbidity and mortality mainly from cardiovascular complications. The exacerbation of vascular disease is accelerated by diabetes, and coexisting hypertension will greatly increase this risk (Christlieb et al (1981) Diabetes 30 (Suppl 2): ​​90-96; Krolewski et al (1988) NEngl J Med 318: 140-145.). The mechanism by which diabetes and hypertension coexist and accelerate vascular damage has not yet been clarified. Both conditions involve endothelial dysfunction, inflammatory cell accumulation, vascular smooth muscle cell (VSMC) prol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/6887G01N33/6893G01N2333/475G01N2800/042G01N2800/32
Inventor A·A·贾法W·R·乌辛格
Owner FIBROGEN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com